Claims for Patent: 11,278,544

Summary for Patent: 11,278,544

Title:	Compositions for affecting weight loss
Abstract:	Disclosed are compositions for affecting weight loss comprising a first compound and a second compound, where the first compound is an opioid antagonist and the second compound causes increased agonism of a melanocortin 3 receptor (MC3-R) or a melanocortin 4 receptor (MC4-R) compared to normal physiological conditions. Also disclosed are methods of affecting weight loss, increasing energy expenditure, increasing satiety in an individual, or suppressing the appetite of an individual, comprising identifying an individual in need thereof and treating that individual to antagonize opioid receptor activity and to enhance .alpha.-MSH activity.
Inventor(s):	Weber; Eckard (San Diego, CA), Cowley; Michael Alexander (Portland, OR)
Assignee:	Nalpropion Pharmaceuticals LLC (Morristown, NJ)
Application Number:	16/363,206
Patent Claims:	1. A method of treating overweight or obesity, the method comprising administering to a patient in need thereof a therapeutically effective amount comprising 30 mg to 500 mg of bupropion, or a pharmaceutically acceptable salt thereof, and a therapeutically effective amount comprising 5 mg to 50 mg of naltrexone, or a pharmaceutically acceptable salt thereof, wherein the bupropion or pharmaceutically acceptable salt thereof is in a sustained-release formulation. 2. The method of claim 1, wherein the naltrexone or pharmaceutically acceptable salt thereof is in a sustained-release formulation. 3. The method of claim 1, wherein the therapeutically effective amount comprises 30 mg to 300 mg of bupropion or a pharmaceutically acceptable salt thereof. 4. The method of claim 1, wherein the naltrexone or pharmaceutically acceptable salt thereof and bupropion or pharmaceutically acceptable salt thereof are administered simultaneously. 5. The method of claim 1, wherein the naltrexone or pharmaceutically acceptable salt thereof and bupropion or pharmaceutically acceptable salt thereof are provided in a single oral dosage form. 6. The method of claim 1, wherein the naltrexone or pharmaceutically acceptable salt thereof is administered prior to the bupropion or pharmaceutically acceptable salt thereof. 7. The method of claim 1, wherein the naltrexone or pharmaceutically acceptable salt thereof is administered subsequent to the bupropion or pharmaceutically acceptable salt thereof.